drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Monoclonal antibody inhibitor of CCR8 that targets CCR8-expressing intratumoral regulatory T cells (Tregs) to block CCR8 signaling and/or deplete CCR8+ Tregs, aiming to relieve immunosuppression in the tumor microenvironment.
nci_thesaurus_concept_id
C200059
nci_thesaurus_preferred_term
Anti-CCR8 Monoclonal Antibody ZL-1218
nci_thesaurus_definition
A humanized immunoglobulin G1 (IgG1) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody ZL-1218 targets and binds to CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME), and depletes CCR8-positive tumor-infiltrating Tregs via antibody-dependent cellular cytotoxicity (ADCC). This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression.
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 anti-CCR8 monoclonal antibody that binds CCR8 on intratumoral regulatory T cells, blocks CCR8 signaling and depletes CCR8+ Tregs via ADCC, reducing immunosuppression in the tumor microenvironment and restoring antitumor immunity.
drug_name
ZL-1218
nct_id_drug_ref
NCT05859464